46 Pre-specified exploratory subgroup analyses showed a trend toward benefit in advanced stage, HER2 under-expression, and triple-negative breast cancer, supporting further investigation in these specific subsets of patients.
← all excerpts
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar.
2
—
—
The sentences
Notably, there was a strong trend toward improved PFS in patients with brain metastases.